Psychedelic drugs are gaining popularity in the pharmaceutical industry because of their benefits for people suffering with psychiatric disorders. Groundbreaking work at Imperial College suggests that psilocybin in Magic Mushrooms ‘resets’ brain activity in people with depression, while MDMA may help those with PTSD.
Join a trip with world experts Dr David Erritzoe, Professor Christine Hauskeller, Charlotte Walsh, and Ritula Shah to look at the medical, societal, and historical implications of these recent discoveries.